BEVERLY HILLS, Calif., Nov. 22, 2010 /PRNewswire/ -- OXIS International, Inc., (OTC Bulletin Board: OXIS; Euronext Paris: OXI) today announced that the "First International Congress on Ergothioneine, Anti-Oxidants, and Age Management Medicine" will be held Friday to Sunday, July 15-17, 2011, in the DeNeve Auditorium at the University of California, Los Angeles.

In addition to the specific dates and venue, OXIS announced that the keynote speaker on Saturday the 16th will be Steven G. Clarke, Ph.D., Professor of Biochemistry at UCLA and Director, UCLA Molecular Biology Institute.

"We are very pleased to have Dr. Clarke deliver the keynote speech at this important meeting on Ergothioneine," said Bernie Landes, president of OXIS International.  "He is a leader in the research on aging and rejuvenation, and will provide excellent background and context to the event's discussions of Ergothioneine and oxidative stress."

The Congress is being organized by OXIS' distinguished Science Advisory Board (SAB).  In addition to the keynote address, members of the SAB will make presentations focusing on their specific areas of expertise relating to Ergothioneine, including:

    --  Dr. Okezie Aruoma, President of the OXIS SAB and founding faculty member
        of the Tuoro School of Pharmacy, discussing the latest research on the
        biochemistry of Ergothioneine and its relationship to key chronic
        disease states, including diabetes, cardiovascular disease, cancer and
        arthritis.
    --  Dr. John Repine, Director of the Webb-Waring Institute at the University
        of Colorado, a leading center for the study of oxidative stress related
        conditions, presenting the latest clinical research regarding the use of
        powerful new antioxidants, including Ergothioneine, in developing novel
        approaches to prevention and treatment.
    --  Dr. Steven Coles, a world authority on healthy aging and extreme
        longevity delivering the latest related findings in these increasingly
        important areas of research.

OXIS International is also now soliciting submissions for presentations at the Congress, which should be sent to blandes@oxis.com.

OXIS plans to provide further details regarding the event, including registration information, in early 2011.

About OXIS International, Inc.

OXIS International, Inc. develops technologies and products to research, diagnose, treat and prevent diseases of oxidative stress/inflammation associated with damage from free radical and reactive oxygen species (ROS). The company holds the rights to several therapeutic classes of compounds in the area of oxidative stress, and has focused commercialization programs that include SOD (superoxide dismutase), MPO (myeloperoxidase), GPx (glutathione peroxidase), as well as a highly potent antioxidant, Ergothioneine, that may be sold over-the-counter (OTC) as a dietary supplement. Ergothioneine can also be sold to the cosmetics markets as well as the functional food and beverage markets.  For more information, please visit www.oxis.com

Forward-Looking Statements

Any statements in this press release that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words "project," "believe," "anticipate," "plan," "expect," "estimate," "intend," "should," "would," "could," "will," "may," "potential" or the negative of those words or other similar expressions words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risks and uncertainties inherent in our business, including, without limitation the risks of obtaining possibly required regulatory approvals, the timing of product introductions, the level of market acceptance of and continuing demand for the Company's products, the impact of competitive products and pricing and the Company's ability to obtain additional financing to support its operations. We refer you to the risks and factors detailed from time to time in the Company's Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q.  Any forward-looking statements in this press release represent the Company's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company anticipates that subsequent events and developments may cause its views to change, and the Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.

SOURCE OXIS International, Inc.